Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 2,358 Shares of Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) insider John Fesko sold 2,358 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $65.09, for a total transaction of $153,482.22. Following the transaction, the insider now owns 108,494 shares of the company’s stock, valued at approximately $7,061,874.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Natera Trading Down 0.6 %

NTRA stock opened at $66.00 on Wednesday. The company has a market capitalization of $7.93 billion, a PE ratio of -14.60 and a beta of 1.28. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $68.92. The firm’s 50-day moving average is $60.92 and its 200 day moving average is $52.89. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.37 and a quick ratio of 4.23.

Natera (NASDAQ:NTRAGet Free Report) last posted its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.01. The company had revenue of $268.30 million for the quarter, compared to the consensus estimate of $259.27 million. Natera had a negative net margin of 50.50% and a negative return on equity of 72.98%. The firm’s revenue was up 27.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.25) EPS. On average, research analysts anticipate that Natera, Inc. will post -3.88 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on NTRA shares. UBS Group lowered their price objective on shares of Natera from $76.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, November 9th. Wolfe Research started coverage on shares of Natera in a research report on Wednesday, December 13th. They set an “outperform” rating and a $70.00 price objective for the company. TD Cowen increased their price objective on shares of Natera from $82.00 to $87.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Stephens restated an “overweight” rating and issued a $78.00 target price on shares of Natera in a report on Tuesday. Finally, Piper Sandler lowered their target price on shares of Natera from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, October 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $71.54.

Get Our Latest Stock Report on Natera

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NTRA. Bank of New York Mellon Corp increased its position in Natera by 6.7% during the 1st quarter. Bank of New York Mellon Corp now owns 820,974 shares of the medical research company’s stock valued at $33,399,000 after purchasing an additional 51,791 shares during the period. US Bancorp DE boosted its stake in Natera by 20.0% in the 1st quarter. US Bancorp DE now owns 16,180 shares of the medical research company’s stock worth $658,000 after purchasing an additional 2,698 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Natera by 215.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company’s stock worth $83,000 after purchasing an additional 1,399 shares in the last quarter. Bank of Montreal Can boosted its stake in Natera by 80.6% in the 1st quarter. Bank of Montreal Can now owns 130,062 shares of the medical research company’s stock worth $5,390,000 after purchasing an additional 58,049 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Natera in the 1st quarter worth approximately $209,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Articles

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.